CIPO trademark

TEVA & Design

RegisteredCIPOFigurative markClass 5

"TEVA & Design" is a figurative mark owned by Teva Pharmaceutical Industries Ltd., filed at the CIPO on May 4, 2017. It is registered and covers class 5 (Pharmaceuticals).

View Teva Pharmaceutical Industries Ltd. portfolio Get this data via the API

Data current as of June 14, 2025Official CIPO record

As filed with the CIPO

Status: Registered; Since November 20, 2019
Filed: May 4, 2017
Registered: November 20, 2019
Expires: November 20, 2029
Application no.: 1835947
Registration no.: TMA1063769
Office: CIPO; Canadian Intellectual Property Office
Mark type: Figurative mark; 1 class

Ownership

Who owns TEVA & Design

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Teva Pharmaceutical Industries Ltd.

Israel

1,141 trademarks in the portfolioView company

Representative

Osler, Hoskin & Harcourt LLP

Goods and services

What the mark covers

The products and services TEVA & Design is filed for, grouped by Nice class.

05Class 5 · Pharmaceuticals
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders, namely, Parkinson's disease and spinal muscular atrophy; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders, namely, carpal tunnel syndrome and connective tissue diseases; Pharmaceutical preparations for the prevention and treatment of digestive tract and gastrointestinal diseases and disorders; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, namely, dermatitis, eczema and psoriasis; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents for the treatment of the central nervous system, namely, for treating encephalitis, epilepsy, cerebral palsy, multiple sclerosis and Huntington's disease; Pharmaceutical agents for the treatment of circulatory systems, namely, for treating atherosclerosis, aneurysms and Raynaud's disease; Pharmaceutical agents affecting sensory organs, namely, for treating hearing loss and glaucoma; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases and incontinence.

History

What has happened so far

Steps recorded by the CIPO, newest first.

February 28, 2022Voir Preuve au dossier/See evidence on File No. 2121983
February 28, 2022Amendment to Registration; Owner Address Change / Voir Preuve au dossier/See evidence on File No. 2121983
November 20, 2019Registered
June 20, 2019Registration Fee Notice Sent
June 20, 2019Registration Pending
March 20, 2019Advertised; Vol.66 Issue 3360
February 28, 2019Approved; APPROVED BY PROGRAM EX200M1
January 8, 2019Agent Changed; From: 2520 To: 69 / Voir Preuve au dossier/See evidence on File No. 1839341
January 8, 2019Rep for Service Changed; From: 2520 To: 69 / Voir Preuve au dossier/See evidence on File No. 1839341
January 8, 2019Approval Notice Sent

6 earlier steps on the official record.

FAQ

About TEVA & Design

Who owns the trademark "TEVA & Design"?

The CIPO trademark "TEVA & Design" (application 1835947) is owned by Teva Pharmaceutical Industries Ltd.

What is the status of "TEVA & Design"?

Its status at the CIPO is: registered.

When was "TEVA & Design" registered?

It was registered on November 20, 2019 and is due to expire on November 20, 2029.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull TEVA & Design and marks like it into your own product with one request.

GET/v1/trademarks/{id}
The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/events
Every step in the office history
GET/v1/proceedings?trademark_id={id}
Oppositions and cancellations against the mark

Get API key View docs

GET /v1/trademarks/{id}

ID=tm_019deb66-d63c-71b5-988e-eec0b37ddaa5
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"

Response

{
  "id": "tm_019deb66-d63c-71b5-988e-eec0b37ddaa5",
  "object": "trademark",
  "mark_text": "TEVA & Design",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "CA",
  "application_number": "1835947",
  "filing_date": "2017-05-04",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "TEVA PHARMACEUTICAL INDUSTRIES LTD.",
      "entity_id": "ent_019ebbc5-6f32-7092-a649-5aaa7b712e21"
    }
  ]
}